| A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. | |
| | |
MedLine Citation:
|
PMID: 18158435 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare characteristics and outcomes of patients treated with drotrecogin alfa (activated) (DrotAA) in clinical practice to those treated in a phase III randomized controlled trial (PROWESS). DESIGN: Observational data were collected retrospectively from patients who received DrotAA as part of physician-directed treatment. SETTING: Intensive care units of five teaching institutions. PATIENTS: Patients were > or = 18 yrs old, had severe sepsis (confirmed/suspected infection with one or more sepsis-induced organ dysfunctions), and received DrotAA. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Baseline demographics, severity of illness, time from organ dysfunction onset to DrotAA treatment, daily assessment of organ dysfunction, serious bleeding events, and in-hospital mortality were reported. Timing from severe sepsis documentation to start of DrotAA infusion was categorized: day 0 (same calendar day); day 1 (next calendar day); and day > or = 2 (second calendar day or later). Clinical practice patients (n = 274) were younger, had more comorbidities, had higher severity of illness (as measured by organ dysfunction or greater vasopressor/ventilator use), and received DrotAA later than PROWESS patients (all p < .05). Overall hospital mortality for clinical practice patients was 42%, compared with 37% for DrotAA-treated PROWESS patients with Acute Physiology and Chronic Health Evaluation II score > or = 25. Mortality for day 0, day 1, and day > or = 2 groups was 33%, 40%, and 52%, respectively. In PROWESS, the vast majority were treated on day 0 or day 1. Serious bleeding events during infusion were noted in 4.0% of clinical practice patients compared with 2.2% of PROWESS DrotAA-treated patients with Acute Physiology and Chronic Health Evaluation II score > or = 25. CONCLUSIONS: Patients treated in clinical practice differed from those in PROWESS. Patients were younger, had more comorbidities, had greater severity of illness, and had longer mean time from severe sepsis onset to the start of DrotAA. Hospital mortality for patients treated within 1 day of severe sepsis onset was similar to DrotAA-treated PROWESS patients. While the low number of serious bleeding events precludes a definitive assessment, the observed incidence of serious bleeding events in clinical practice patients was numerically higher than in DrotAA-treated PROWESS patients. |
| | |
Authors:
|
Arthur Wheeler; Jay Steingrub; Gregory A Schmidt; Philip Sanchez; Judith Jacobi; Walter Linde-Zwirble; Becky Bates; Rebecca L Qualy; Brad Woodward; Michael Zeckel |
Related Documents
:
|
11822945 - Predictive factors associated with the development of abdominal compartment syndrome in... 343895 - 5. new approaches to the management of flail chest. 16049385 - The use of recombinant human activated protein c (rhapc) in the treatment of severe sep... 19268905 - Severity of disease as main predictor for mortality in patients with pyogenic liver abs... 2989515 - Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated... 12270565 - Tension-free vaginal tape (tvt) in the treatment of urinary stress incontinence: 3 year... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Critical care medicine Volume: 36 ISSN: 1530-0293 ISO Abbreviation: Crit. Care Med. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-25 Completed Date: 2008-02-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0355501 Medline TA: Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 14-23 Citation Subset: AIM; IM |
Affiliation:
|
Vanderbilt Medical Center, Nashville, TN, USA. art.wheeler@vanderbilt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
APACHE Adult African Americans / statistics & numerical data Age Distribution Anti-Infective Agents / therapeutic use* Cardiomyopathies / epidemiology Clinical Trials, Phase III as Topic Comorbidity Female Hemorrhage / epidemiology Hospital Mortality Humans Liver Diseases / epidemiology Male Middle Aged Neoplasms / epidemiology Observation Professional Practice / statistics & numerical data* Protein C / therapeutic use* Recombinant Proteins / therapeutic use Retrospective Studies Sepsis / drug therapy*, epidemiology* United States / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Infective Agents; 0/Protein C; 0/Recombinant Proteins; 0/drotrecogin alfa activated |
| Comments/Corrections | |
Comment In:
|
Crit Care Med. 2008 Jan;36(1):332-3
[PMID:
18158441
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic pain: second, do no harm.
Next Document: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock...